Global Immunohematology Market 2026 by Company, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Immunohematology market size was valued at US$ 2636 million in 2025 and is forecast to a readjusted size of US$ 3495 million by 2032 with a CAGR of 4.5% during review period.
Commercially, immunohematology usually refers to pre-transfusion compatibility testing and blood-group serology/molecular typing solutions. The core menu includes ABO/Rh typing, antibody screening, antibody identification, crossmatching, DAT/IAT, antigen typing/extended phenotyping, and selected molecular typing for rare or complex cases. Product formats span gel/cards, reagent red cells, antisera, QC materials, fully/semi-automated analyzers, data-management software, and in some cases reference-laboratory testing services. Upstream inputs include antibodies, reagent RBC materials, plastics/consumables, automation modules, and software; midstream is reagent–instrument system integration; downstream customers are primarily hospital transfusion laboratories/blood banks, independent labs, blood centers, and reference labs.
Immunohematology, as a core interdisciplinary field integrating immunology and hematology, focuses on the interaction between blood components and the immune system, covering key areas such as blood grouping, transfusion safety, diagnosis and treatment of autoimmune hematological diseases, and hematopoietic stem cell transplantation matching. It is an important part of the global healthcare system, and its development is closely linked to multiple global trends, including the upgrading of clinical needs, breakthroughs in technological innovation, and the protection of public health security. The continuous growth of global clinical transfusion demand and the continuous improvement of transfusion safety standards are the core driving forces. The demand for safe blood transfusion in various surgeries, chronic diseases and trauma treatment has promoted the transformation of immunohematology technology towards precision and standardization, reducing the risk of transfusion adverse reactions. The clinical diagnosis and treatment needs of hematological tumors, autoimmune hematological diseases and other diseases have promoted the discipline to extend towards precise immunotherapy and personalized diagnosis and treatment, broadening the research and application boundaries. Technological innovation continues to empower the industry. The application of automated detection platforms, molecular typing technologies, AI-assisted interpretation systems and other technologies has improved detection efficiency and accuracy, promoting the discipline to develop in a diversified and cross-integrated direction. The improvement of the global public health system and the enhancement of blood safety awareness have promoted countries to strengthen blood screening, rare blood type bank construction and standardized construction of immunohematology laboratories. At the same time, the upgrading of medical infrastructure in emerging markets has released new growth for the development of the discipline. The global cooperation between leading enterprises and scientific research institutions has accelerated the global popularization of technological achievements.
Despite the continuous development of the global immunohematology field and the increasing clinical value, it still faces many challenges. High-end technologies and core reagent barriers are strict. The core technologies of precise molecular typing, high-end detection equipment and key reagents are monopolized by a few international leading enterprises. Emerging markets and developing countries have insufficient investment in scientific research, making it difficult to achieve technological breakthroughs and independent substitution, resulting in unbalanced distribution of medical resources. There are regional differences in the development of the discipline. Developed countries, relying on mature medical systems and scientific research strength, focus on cutting-edge technology research and development and clinical application, occupying a dominant position in the industry. However, some developing countries, limited by medical resources and professional talents, have insufficient accessibility of immunohematology detection and diagnosis and treatment services. There is a gap between clinical application and technological transformation. Some cutting-edge technologies have high R&D costs and long certification cycles, making it difficult to quickly land and popularize. At the same time, the shortage of professional and technical talents restricts the promotion and application of disciplinary technologies. In addition, there are regional differences in global industry standards and regulatory norms. Different countries have different requirements for detection processes, reagent certification and quality control, increasing the difficulty of cross-border promotion of technologies and products. Coupled with the safety and ethical controversies of some technologies, the balanced and high-quality development of global immunohematology is further restricted.
This report is a detailed and comprehensive analysis for global Immunohematology market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Immunohematology market size and forecasts, in consumption value ($ Million), 2021-2032
Global Immunohematology market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Immunohematology market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Immunohematology market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Immunohematology
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Immunohematology market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bio-Rad Laboratories, Grifols, Immucor (Werfen), QuidelOrtho, Beckman Coulter, DIAGAST, Hemo bioscience, Institut de Biotechnologies Jacques Boy, MTC INVITRO, AliveDx, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Immunohematology market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Immunohematology Analyzers and Systems
Immunohematology Reagent
Market segment by Downstream Customers
Hospital Transfusion Department/Blood Bank
Blood Center/Blood Collection and Supply Institution
Reference Laboratory/Transplant Center
Others
Market segment by Clinical Complexity
Conventional High Frequency
High Complexity/High Added Value
Market segment by Application
Blood-Related Diseases
HIV
Hepatitis
Market segment by players, this report covers
Bio-Rad Laboratories
Grifols
Immucor (Werfen)
QuidelOrtho
Beckman Coulter
DIAGAST
Hemo bioscience
Institut de Biotechnologies Jacques Boy
MTC INVITRO
AliveDx
AI KANG
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Immunohematology product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Immunohematology, with revenue, gross margin, and global market share of Immunohematology from 2021 to 2026.
Chapter 3, the Immunohematology competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Immunohematology market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Immunohematology.
Chapter 13, to describe Immunohematology research findings and conclusion.